RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:639

Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG

high confidenceDisorder

Also known as: Anti-MAG neuropathy · Neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein

Publications

330

71th percentile

Trials

7

Interventional, condition-specific

Researchers

1,048

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

anti-MAG neuropathy · neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    330 matched papers (237 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    1 EMA designation (none yet with FDA orphan-indication approval) — e.g. Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1->3)-beta-D-galactopyranoside Source

  6. Interventional trialPresent

    7 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · no FDA orphan-indication approval yet

  • EMA Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1->3)-beta-D-galactopyranosideTreatment of anti-MAG neuropathy · 17/07/2017 · WithdrawnEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

330

330 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

330 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

237 in the last 10 years · high confidence · 71th percentile (publications denominator)

Phrase hits: 330 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,048

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Delmont E14 papers · 2025

    Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, 13385 Marseille, France.

    Papers in Europe PMC
  2. 02
    Briani C13 papers · 2026

    Department of Neurosciences, University of Padova, 35100 Padova, Italy.

    Papers in Europe PMC
  3. 03
    Attarian S12 papers · 2024

    Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, 13385 Marseille, France; Inserm, GMGF, Aix-Marseille University, Marseille, 13385 France. Electronic address: sattarian@ap-hm.fr.

    Papers in Europe PMC
  4. 04
    Visentin A11 papers · 2026

    Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35100 Padova, Italy.

    Papers in Europe PMC
  5. 05
    Rajabally YA9 papers · 2026

    Regional Neuromuscular Clinic, Queen Elizabeth Neurosciences Centre, University Hospitals of Birmingham, Birmingham, United Kingdom. Electronic address: Yusuf.Rajabally@uhb.nhs.uk.

    Papers in Europe PMC
  6. 06
    Boucraut J7 papers · 2024

    Aix-Marseille University, CNR2M, CNRS UMR 7286, Medicine Faculty, Marseille, France; Department of Immunology, Hospital La Conception, Marseille, France.

    Papers in Europe PMC
  7. 07
    Manganelli F7 papers · 2025

    Department of Neuroscience, Reproductive and Odontostomatological Science, University of Naples Federico II, Naples, Italy.

    Papers in Europe PMC
  8. 08
    Trentin L7 papers · 2024

    Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy.

    Papers in Europe PMC
  9. 09
    Grapperon AM6 papers · 2024

    Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, 13385 Marseille, France.

    Papers in Europe PMC
  10. 10
    Nobile-Orazio E6 papers · 2025

    a Department of Medical Biotechnology and Translational Medicine (BIOMETRA) , University of Milan , Milan , Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

7

interventional trials for this specific condition

7 interventional trials matched this specific condition name; 2 currently recruiting in our sample.

Data as of 11 September 2026

7 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.9th percentile).

high confidence · 90.9th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

7 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (6)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG" OR "Anti-MAG neuropathy" OR "Neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG" OR "Anti-MAG neuropathy" OR "Neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 7 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T14:39:56.910Z